Citigroup Upgrades Edwards Lifesciences to Buy, Raises Price Target to $105
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch has upgraded Edwards Lifesciences (NYSE:EW) from Neutral to Buy and raised the price target from $98 to $105.
May 22, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst Joanne Wuensch has upgraded Edwards Lifesciences from Neutral to Buy and raised the price target from $98 to $105.
The upgrade from Neutral to Buy and the increase in the price target from $98 to $105 by a reputable analyst at Citigroup is likely to positively impact the stock price of Edwards Lifesciences in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100